/ N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOTO et al. Art Unit:

Appln. No.: 09/338,063 Examiner: G. Ewoldt

Filed: June 23, 1999 Atty. Docket: 16991.005

For: Monoclonal Antibodies That Bind Confirmation No.: 9916

OCIF

Request to Correct Title in PALM

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Examiner's Amendment of July 14, 2003, the present title of the above-identified application is "Monoclonal Antibodies That Bind OCIF". However, Applicants note that the Office's PALM system apparently contains a misspelling of the word "Antibodies", as evidenced by the attached copy of the Notice of Allowance.

Accordingly, Applicants respectfully request the Examiner to have the title of the above-identified application corrected in the PALM computer system.

Respectfully submitted,

Jbel M. Freed (Reg. No. 25,101) David R. Marsh (Reg. No. 41,408)

June E. Cohan (Reg. No. 43,741)

Dawn Gardner Krosnick (Reg. No. 44,118)

1644

Date: November 12, 2003

ARNOLD & PORTER 555 Twelfth Street, N.W. Washington, D.C. 20004-1206 (202) 942-5000 telephone (202) 942-5999 facsimile



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

OTICE OF ALLOWANCE AND FEE(S) DUE

ANDREW S BRENC

ISSUE FEE/ WRUNGS. Docketec

EXAMINER

ARNOLD & PORTER

ATTN: IP DOCKETING DEPARTMENT ROOM 1126Bje Date 10/14/03

EWOLDT, GERALD R

555 TWELFTH STREET NW WASHINGTON, DC 20004-1206

Initial 40

ART UNIT 1644

CLASS-SUBCLASS 530-389200

DATE MAILED: 07/14/2003

APPLICATION NO.	FILING DATE	FIRST NA	FIRST NAMED INVENTOR		CONFIRMATION NO
09/338,063	06/23/1999	MAS	MASAAKI GOTO		9916
ITLE OF INVENTION: M	ONOCLONAL ANTIDBOD	IES THAT BIND OCIF) misspelle	ed .	
					2.25.015
APPLN, TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
 - Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 4

In re Application of:

GOTO et al.

Appln. No.: 09/338,063

Filed: June 23, 1999

For: MONOCLONAL ANTIBODIES

THAT BIND OCIF

Art Unit: 1644

Examiner: Gerald R. Ewoldt

Atty. Docket: 16991.005

Confirm. No.: 9916

SUBMISSION OF SUBSTITUTE SPECIFICATION & ABSTRACT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith is a substitute specification and abstract for the above-identified application, entry of which is respectfully requested. Clean and marked-up versions of the substitute specification are submitted, with changes shown relative to the immediate prior version of the specification of record as required by 37 C.F.R. § 1.125(c). Concurrently submitted are Formal Drawings and a substitute Sequence Listing.

The substitute specification contains no new matter. The present substitute specification corrects minor typographical and grammatical errors, and also corrects the presentation of various trademarks in the specification. Although the Examiner did not request a substitute specification in the present application, Applicants note that a substitute specification was requested in related Application No. 10/232,858. Correction of typographical and grammatical errors are believed to be self-evident from a review of the marked-up specification, and therefore Applicants limit their comments on the changes made in the substitute specification to the following:

Before paragraph 1, the new title of the application is indicated as amended by the Examiner's Amendment mailed July 14, 2003.

At paragraph 2, the sequence listing has been incorporated by reference as required by 37 C.F.R. § 1.52.

At paragraph 13, the text has been amended to clarify that the protein has molecular weights of 60 kD under reducing conditions, and molecular weights of 60 kD and 120 kD under non-reducing conditions. Support for this amendment may be found in the specification as originally filed, e.g., at current paragraphs 66 and 137.

At paragraph 16, the text has been amended to clarify that the IMR-90 cells are human fetal lung fibroblast cells. Support for this amendment may be found in the specification as originally filed, e.g., at current paragraph 48.

At paragraphs 145, 147, 148, 151, 153, 156 and 158, the amino acid numbers used when referring to SEQ ID NO: 5 have been corrected to match the substitute sequence listing in this application. In the original sequence listing filed in parent application 08/915,004, several amino acid sequences (including SEQ ID NO: 5) were numbered with positive and negative numbers, where the negative numbers referred to amino acids not present in the mature peptides (e.g., signal peptide amino acids had negative numbers). Now that the sequence listing has been brought into compliance with the current 37 C.F.R., all amino acid sequences are now numbered only with positive numbers. The present amendment now brings the specification into compliance with the substitute sequence listing. Support for these amendments may be found in the specification as originally filed, the sequence listing as originally filed in the parent application, and in the substitute sequence listing.

At paragraph 266, Applicants have re-written the deposit information and provided the current name of the international depository in which the accession resides.

At paragraph 267, Applicants have included the text "What is Claimed:" as amended by the Examiner's Amendment mailed July 14, 2003 and Applicants' Amendment of July 29, 2003. Although this substitute specification does <u>not</u> include the actual claims, Applicants desire to include the text of this heading herein.

Should the Examiner have any questions regarding the above-identified application, he is invited to contact the undersigned at the number indicated below.

Respectfully submitted,

Joel M. Freed (Reg. No. 25,101) David R. Marsh (Reg. No. 41,408)

June E. Cohan (Reg. No. 43,741)

Dawn Gardner Krosnick (Reg. No. 44,118)

Date: November 12, 2003

ARNOLD & PORTER 555 Twelfth Street, N.W. Washington, D.C. 20004-1206 (202) 942-5000 telephone (202) 942-5999 facsimile



ARNOLD & PORTER . -

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206



November 12, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: U.S. Application No. 09/338,063

Filed: June 23, 1999

Title: Monoclonal Antibodies That Bind OCIF

Applicants: GOTO *et al.* Atty. Docket: 16991.005

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

- 1. a Submission of Substitute Specification & Abstract;
- 2. a marked-up version of the substitute specification (63 pages plus 1 page Abstract);
- 3. a clean version of the substitute specification (61 pages plus 1 page Abstract);
- 4. a Statement Regarding Sequence Submission;
- 5. a paper copy of a substitute sequence listing (81 pages);
- 6. a sequence listing in Computer Readable Form (CRF), on floppy diskette;
- 7. a Letter to PTO Draftsperson: Submission of Formal Drawings;
- 8. twelve (12) sheets of formal drawings (Figures 1A, 1B, 2, 3, 4A, 4B, and 5-15);
- 9. a Request to Correct Title in PALM including a marked-up copy of the Notice of Allowance and Fee(s) Due form; and
- 10. a return postcard.

Submitted herewith is a sequence listing in Computer Readable Form (CRF), on floppy diskette.

The sequence listing in Computer Readable Form (CRF) contains one file called "SubSeq16991005.txt" which is 136,636 bytes in size (measured in MS-DOS) and was recorded on October 17, 2003.

ARNOLD & PORTER

Commissioner for Patents Atty. Docket: 16991.005 November 12, 2003 Page 2

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees under 37 C.F.R. §§ 1.16 or 1.17 are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter Deposit Account No. 50-2387 referencing matter number 16991.005. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Joel M. Freed (Reg. No. 25,101)

David R. Marsh (Reg. No. 41,408) June E. Cohan (Reg. No. 43,741)

Dawn Gardner Krosnick (Reg. No. 44,118)

Enclosures

In re application of:

GOTO et al.

Appln. No. 09/338,063

Filed: June 23, 1999

For: Monoclonal Antibodies That Bind

OCIF

Art Unit: 1644

Examiner: Gerald R. Ewoldt

Atty. Docket: 16991.005

Confirmation No.: 9916

Letter to PTO Draftsperson: Submission of Formal Drawings

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ATTN: Drawing Review Branch

Sir:

Submitted herewith are formal drawing sheets with Figures 1A, 1B, 2, 3, 4A, 4B, and 5-15 corresponding to the informal drawings submitted with the above-captioned application. The application number and title of the application appear on the front of the sheets.

Acknowledgment of the receipt, approval, and entry of these formal drawings into this application is respectfully requested.

Respectfully submitted,

Joel M. Freed (Reg. No. 25,101) David R. Marsh (Reg. No. 41,408)

June E. Cohan (Reg. No. 43,741)

Dawn Gardner Krosnick (Reg. No. 44,118)

Date: November 12, 2003

ARNOLD & PORTER 555 12th Street, N.W. Washington, DC 20004-1206 202.942.5000 telephone 202.942.5999 facsimile